<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-105841" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pain Management Medications</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Queremel Milani</surname>
            <given-names>Daniel A.</given-names>
          </name>
          <aff>Universidad de Los Andes, Bogot&#x000e1;, Colombia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Davis</surname>
            <given-names>Donald D.</given-names>
          </name>
          <aff>Wellstar Atlanta Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Daniel Queremel Milani declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Donald Davis declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-105841.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Analgesics are medications used in the management and treatment of pain. They include several classes of medications (acetaminophen, nonsteroidal anti-inflammatory drugs, antidepressants, antiepileptics, local anesthetics, and opioids). This activity reviews the indications, actions, and contraindications for all the drug classes listed before as valuable agents in the treatment of pain and other specific disorders. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, monitoring) pertinent for members of the interprofessional healthcare team in the management of patients with acute and chronic pain and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Outline the indication for naloxone administration.</p></list-item><list-item><p>Describe the common physical exam findings associated with nonsteroidal anti-inflammatory drug (NSAID) toxicity.</p></list-item><list-item><p>Identify the most common adverse events associated with acetaminophen therapy.</p></list-item><list-item><p>Review the importance of improving care coordination among the interprofessional team to pain control medication choices for patients with acute and chronic pain.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=105841&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=105841">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-105841.s2" sec-type="Indications">
        <title>Indications</title>
        <p>According to the International Association for the Study of Pain (IASP), pain is defined as an unpleasant experience (sensory and/or emotional) related to a potential or confirmed tissue damage or described in such terms.<xref ref-type="bibr" rid="article-105841.r1">[1]</xref>&#x000a0;Currently, the debate is ongoing whether or not this definition should be modified.<xref ref-type="bibr" rid="article-105841.r2">[2]</xref><xref ref-type="bibr" rid="article-105841.r3">[3]</xref><xref ref-type="bibr" rid="article-105841.r4">[4]</xref>&#x000a0;Nonetheless, the classification for pain management medications is stable; categories are nonopioid analgesic agents and opioid analgesic agents.</p>
        <p>
<bold>Nonopioid analgesic agents</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Acetaminophen (paracetamol)</bold>: Mild to moderate pain, moderate to severe pain (as adjunctive therapy to opioids), and temporary reduction of fever. Acetaminophen should not be used for neuropathic pain since there is no documented effect.<xref ref-type="bibr" rid="article-105841.r5">[5]</xref><xref ref-type="bibr" rid="article-105841.r6">[6]</xref><xref ref-type="bibr" rid="article-105841.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Nonsteroidal anti-inflammatory drugs (NSAIDs)</bold>:&#x000a0;These drugs are used for mild-to-moderate pain, pain associated with inflammation, and temporary reduction of fever. Similar to the previous medication, NSAIDs have no evidence for the management of neuropathic pain. Some NSAIDs have other non-pain-related indications (eg., aspirin use for secondary prevention of myocardial infarction), which will not be covered in this review.<xref ref-type="bibr" rid="article-105841.r7">[7]</xref><xref ref-type="bibr" rid="article-105841.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Antidepressant medications</bold>: Selective serotonin and norepinephrine reuptake inhibitors (SNRIs), particularly duloxetine, &#x000a0;and tricyclic antidepressants (TCAs), especially&#x000a0;amitriptyline, have demonstrated&#x000a0;efficacy in a variety of neuropathic pain conditions. Thus they are recommended as the first line of treatment.<xref ref-type="bibr" rid="article-105841.r9">[9]</xref>&#x000a0;Furthermore, besides their respective indications for psychiatric disorders such as major depressive disorder and generalized anxiety disorder, these medications&#x000a0;are indicated for other pathologies such as fibromyalgia and chronic musculoskeletal pain. Also, antidepressants are recommended as a&#x000a0;prophylactic treatment for&#x000a0;migraine and tension-type headaches (amitriptyline). Both of the pharmacological groups seem to&#x000a0;be more effective in patients with depressive symptoms and pain as comorbidity than in those patients with pain alone.<xref ref-type="bibr" rid="article-105841.r7">[7]</xref><xref ref-type="bibr" rid="article-105841.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Antiepileptic medications</bold>: Several antiepileptic drugs are also known for their&#x000a0;analgesic properties through their mechanism of action&#x000a0;of lowering neurotransmitter release or neuronal firing. The most common antiepileptics used for pain treatment are&#x000a0;gabapentin and pregabalin.<xref ref-type="bibr" rid="article-105841.r7">[7]</xref>
<list list-type="bullet"><list-item><p>Gabapentin: Postherpetic neuralgia in adults and neuropathic pain.</p></list-item><list-item><p>Pregabalin: Neuropathic pain associated with diabetic peripheral neuropathy or&#x000a0;spinal cord injury, postherpetic neuralgia, and fibromyalgia.</p></list-item><list-item><p>Oxcarbazepine and&#x000a0;carbamazepine:&#x000a0;trigeminal or glossopharyngeal neuralgia</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Local anesthetics</bold>: Lidocaine is among the most commonly used medications&#x000a0;in this drug class, which is FDA approved for postherpetic neuralgia and recommended for peripheral neuropathic pain.<xref ref-type="bibr" rid="article-105841.r7">[7]</xref><xref ref-type="bibr" rid="article-105841.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Opioid Agents</bold>
</p>
        <p>Opioids are a broad&#x000a0;class of medications with structural resemblance to the natural plant alkaloids found in opium, which was originally derived from the resin of the opium poppy, <italic toggle="yes">Papaver somniferum</italic>.<xref ref-type="bibr" rid="article-105841.r11">[11]</xref><bold>&#x000a0;</bold>They&#x000a0;are recognized as the most effective and widely used drugs in treating severe pain.<xref ref-type="bibr" rid="article-105841.r12">[12]</xref>&#x000a0;Opioids&#x000a0;have&#x000a0;been among the most controversial analgesics, particularly because of their potential for addiction, tolerance, and side effects.<xref ref-type="bibr" rid="article-105841.r13">[13]</xref>&#x000a0;Although opioids have indications for acute and chronic pain treatment, the&#x000a0;Center for Disease Control and Prevention's guidelines recommends that only&#x000a0;if the expected benefits for both pain and function outweigh the risks, clinicians should prescribe opioids at the&#x000a0;lowest effective dose and for the shortest expected duration to treat the pain severe enough to require opioids.<xref ref-type="bibr" rid="article-105841.r14">[14]</xref><xref ref-type="bibr" rid="article-105841.r15">[15]</xref><xref ref-type="bibr" rid="article-105841.r16">[16]</xref><xref ref-type="bibr" rid="article-105841.r17">[17]</xref></p>
      </sec>
      <sec id="article-105841.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>
<italic toggle="yes">
<bold>Nonopioid analgesic agents</bold>
</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Acetaminophen (paracetamol)</bold>:&#x000a0;The precise mechanism of action for this drug remains unclear to date. Although it&#x000a0;is considered for some as a nonsteroidal anti-inflammatory drug (NSAID), acetaminophen&#x000a0;lacks anti-inflammatory properties and does not bind to the active site of either cyclooxygenase (COX) enzymes (COX-1 or COX-2). However, there is a hypothesis&#x000a0;that acetaminophen inhibits a different&#x000a0;variant of COX-1, also known as&#x000a0;COX-3, but this event remains unconfirmed in human studies. Nonetheless,&#x000a0;the diminished activity of the&#x000a0;COX pathway leads to decreased&#x000a0;prostaglandin synthesis in the central nervous system, thus&#x000a0;inducing&#x000a0;<italic toggle="yes">analgesia</italic>&#x000a0;(serotonergic inhibitory pathways) and <italic toggle="yes">antipyresis </italic>(hypothalamic heat-regulating center).<xref ref-type="bibr" rid="article-105841.r5">[5]</xref><xref ref-type="bibr" rid="article-105841.r6">[6]</xref><xref ref-type="bibr" rid="article-105841.r18">[18]</xref><xref ref-type="bibr" rid="article-105841.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Nonsteroidal anti-inflammatory drugs (NSAIDs)</bold>: The primary mechanism of action is the inhibition of the cyclooxygenase enzyme, thereby inhibiting prostaglandin synthesis. Drugs in this group are categorized according to chemical structure and selectivity: acetylated salicylates (<italic toggle="yes">aspirin</italic>), non-acetylated salicylates (<italic toggle="yes">diflunisal</italic>), propionic acids (<italic toggle="yes">ibuprofen, naproxen</italic>), acetic acids (<italic toggle="yes">indomethacin, diclofenac</italic>), anthranilic acids (<italic toggle="yes">meclofenamate, mefenamic acid</italic>), enolic acids (<italic toggle="yes">meloxicam, piroxicam</italic>), naphthylalanine (<italic toggle="yes">nabumetone</italic>), and selective COX-2 inhibitors (<italic toggle="yes">celecoxib</italic>, <italic toggle="yes">etoricoxib</italic>). Most NSAIDs inhibit both COX isoforms (COX-1 and COX-2) with little selectivity. However, those that do bind with higher affinity to one or another (eg., aspirin, and the coxibs) will exert anti-inflammatory, analgesic, and antipyretic effects at different degrees. For this reason, low doses of aspirin manifest&#x000a0;an&#x000a0;<italic toggle="yes">antiplatelet</italic>&#x000a0;effect, while high doses exhibit an analgesic effect.<xref ref-type="bibr" rid="article-105841.r8">[8]</xref><xref ref-type="bibr" rid="article-105841.r20">[20]</xref><xref ref-type="bibr" rid="article-105841.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Antidepressant medications</bold>: Both tricyclic antidepressants (TCAs) and selective serotonin and norepinephrine reuptake inhibitors (SNRIs) inhibit the reuptake of two important neurotransmitters: serotonin and noradrenaline. This inhibition increases&#x000a0;the descending inhibitory pathways of the central nervous system related to pain. Additionally, TCAs also act on cholinergic, histamine, beta2 adrenergic, opioid,&#x000a0;and N-methyl-D- aspartate (NMDA) receptors, and sodium channels.<xref ref-type="bibr" rid="article-105841.r7">[7]</xref><xref ref-type="bibr" rid="article-105841.r9">[9]</xref><xref ref-type="bibr" rid="article-105841.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Antiepileptic medications</bold>: Both gabapentin and pregabalin&#x000a0;are ligands to&#x000a0;the &#x003b1;&#x003b4; subunit of the voltage-dependent calcium channels, which overexpress in patients with neuropathic pain. By reducing this&#x000a0;calcium-dependent release of excitatory neurotransmitters, these drugs&#x000a0;decrease&#x000a0;neuronal excitability.<xref ref-type="bibr" rid="article-105841.r7">[7]</xref><xref ref-type="bibr" rid="article-105841.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Local anesthetics</bold>: As with other local anesthetics, lidocaine stabilizes the neuronal membrane by inhibiting sodium ion channels on the internal surface of nerve cell membranes. Thus,&#x000a0;pain conduction through nerve impulses becomes&#x000a0;impaired at the site of action, which contributes to&#x000a0;the&#x000a0;absence of systemic effects.<xref ref-type="bibr" rid="article-105841.r24">[24]</xref></p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">
<bold>Opioid agents</bold>
</italic>
</p>
        <p>The majority of the clinically relevant opioids&#x000a0;act primarily at the &#x0201c;mu receptors&#x0201d; and thus are considered &#x0201c;mu agonists.&#x0201d;<xref ref-type="bibr" rid="article-105841.r25">[25]</xref>&#x000a0;Nonetheless, opioids may also act on other&#x000a0;receptors: <italic toggle="yes">kappa</italic>, <italic toggle="yes">delta</italic>, and <italic toggle="yes">sigma</italic> (all of them, including <italic toggle="yes">mu</italic>, are&#x000a0;G protein-coupled receptors). Depending on which&#x000a0;receptor is activated, different physiologic effects occur (i.e., spinal and supraspinal analgesia). Opioids exert their effects&#x000a0;on both presynaptic and postsynaptic neurons. Presynaptically, opioids block calcium channels on nociceptive afferent nerves, thus inhibiting the release of neurotransmitters such as substance P and glutamate. Postsynaptically, opioids enhance&#x000a0;the activity of potassium channels, thus&#x000a0;hyperpolarizing cell membranes and increasing the required action potential to generate nociceptive neurotransmission.<xref ref-type="bibr" rid="article-105841.r12">[12]</xref><xref ref-type="bibr" rid="article-105841.r17">[17]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-105841.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<italic toggle="yes">
<bold>Nonopioid analgesic agents</bold>
</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Acetaminophen (paracetamol)</bold>: The recommended dose for adults is 650 mg to 1000 mg every 4 to 6 hours, a maximum of 4 grams/day.&#x000a0;In children, the recommended dose is 15 mg/kg every 6 hours, up to 60 mg/kg/day.<xref ref-type="bibr" rid="article-105841.r26">[26]</xref>&#x000a0;Acetaminophen is available to&#x000a0;be administered orally (tablet, capsule, syrup, oral solution, or suspension), rectally (rectal suppository), or intravenously.<xref ref-type="bibr" rid="article-105841.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Nonsteroidal anti-inflammatory drugs (NSAIDs)</bold>: Currently, more than 20 different NSAIDs are commercially available. The choice of the agent&#x000a0;depends upon several factors (eg., comorbidities, risk of bleeding). Also, the response to different NSAIDs vary&#x000a0;between patients, and the mechanisms for these distinct responses are only partially understood. Thus, doses depend on the specific drug, and the recommendation is to prescribe the lowest effective dose for each patient for the shortest period. Listed below are various commonly known NSAIDs with their respective doses for analgesia and anti-inflammation:
<list list-type="bullet"><list-item><p><italic toggle="yes">Aspirin (acetylsalicylic acid)</italic>: Is dosed 325 to 650 mg every 4 to 6 hours. The maximum dose is 4000 mg/day. Aspirin is available for oral (caplet, capsule, tablet) or rectal (suppository) administration.</p></list-item><list-item><p><italic toggle="yes">Diclofenac</italic>:&#x000a0;50 mg every 8 hours.&#x000a0;The maximum daily dose is&#x000a0;150 mg. Diclofenac is available for oral (tablet, capsule, packet), intravenous,&#x000a0;topical (cream, gel, patch, solution), or ophthalmic administration.</p></list-item><list-item><p><italic toggle="yes">Ibuprofen</italic>:&#x000a0;It is dosed 400 mg every 4 to 6 hours. The maximum daily dose is&#x000a0;3200 mg (acute) or 2400 mg (chronic). Ibuprofen is available for oral (capsule, tablet, suspension) or intravenous administration.</p></list-item><list-item><p><italic toggle="yes">Indomethacin</italic>: Immediate release: 25 to 50 mg every 8 to 12 hours.&#x000a0;Controlled release: 75 mg once or twice daily. The maximum dose is&#x000a0;150 mg/day. Indomethacin is available for oral (capsule, suspension), intravenous, or rectal (suppository) administration.</p></list-item><list-item><p><italic toggle="yes">Meloxicam</italic>:&#x000a0;Dosing is 7.5 to 15 mg once daily. The maximum daily dose is&#x000a0;15 mg. Meloxicam is available for oral (tablet, capsule, suspension) or intravenous administration.</p></list-item><list-item><p><italic toggle="yes">Naproxen</italic>: 250 to 500 mg every 12 hours (naproxen base) or 275 to 550 mg every 12 hours (naproxen sodium). The maximum daily dose is 1250 mg acute or 1000 mg chronic for naproxen base and&#x000a0;1375 mg acute or 1100 mg chronic for naproxen sodium. Naproxen is available for oral (capsule, suspension, tablet) administration only.</p></list-item><list-item><p><italic toggle="yes">Celecoxib</italic>:&#x000a0;200 mg daily or 100 mg every 12 hours. The maximum dose is&#x000a0;400 mg/day. Celecoxib is available for oral (capsule) administration only.<xref ref-type="bibr" rid="article-105841.r5">[5]</xref><xref ref-type="bibr" rid="article-105841.r6">[6]</xref><xref ref-type="bibr" rid="article-105841.r27">[27]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Antidepressant medications</bold>:&#x000a0;Among the tricyclic antidepressants and selective serotonin and norepinephrine reuptake inhibitors, amitriptyline and duloxetine have the best-documented analgesic effects, respectively.
<list list-type="bullet"><list-item><p><italic toggle="yes">Amitriptyline</italic>: Dosing is 25&#x000a0;to 150 mg orally&#x000a0;(tablet) once daily or in two divided doses. The maximum single and daily doses are 75 mg and 150 mg, respectively. Caution must be taken in patients 65 years old or older with maximum daily doses above 75 mg.&#x000a0;</p></list-item><list-item><p><italic toggle="yes">Duloxetine</italic>: Dosing is 60&#x000a0;to 120 mg orally&#x000a0;(capsule) once daily or in two divided doses. The maximum daily dose is 120 mg.<xref ref-type="bibr" rid="article-105841.r7">[7]</xref><xref ref-type="bibr" rid="article-105841.r28">[28]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Antiepileptic medications</bold>:&#x000a0;
<list list-type="bullet"><list-item><p><italic toggle="yes">Gabapentin</italic>: 300&#x000a0;to 600 mg orally&#x000a0;(capsule, tablets, solution) three times per day with a maximum daily dose of 1800 mg for postherpetic neuralgia or&#x000a0;300&#x000a0;to 1200 mg orally&#x000a0;three times per day with a maximum daily dose of 3600 mg.<xref ref-type="bibr" rid="article-105841.r7">[7]</xref><xref ref-type="bibr" rid="article-105841.r29">[29]</xref></p></list-item><list-item><p><italic toggle="yes">Pregabalin</italic>: 300&#x000a0;to 600 mg/day orally in two divided doses.<xref ref-type="bibr" rid="article-105841.r7">[7]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Local anesthetics</bold>:
<list list-type="bullet"><list-item><p><italic toggle="yes">Lidocaine</italic>: As a patch, lidocaine is available at a concentration of&#x000a0;1.8% or 5%. The recommendation is to apply 1-3 patches to intact skin for up to 12 hours/day. Other commercially available presentations include topical solutions, creams, gels, ointment, and lotions.<xref ref-type="bibr" rid="article-105841.r7">[7]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">
<bold>Opioid agents</bold>
</italic>
</p>
        <p>Opioids are available in diverse dosage forms to use for several routes of administration: oral, transdermal, intramuscular, intravenous, subcutaneous infusion, rectal, epidural, intrathecal, intranasal, and transmucosal.<xref ref-type="bibr" rid="article-105841.r17">[17]</xref><xref ref-type="bibr" rid="article-105841.r30">[30]</xref>&#x000a0;The rationale for each route of administration, dosage range, and dosage form is dependent on a number of factors. For more detailed information, please review the American Pain Society guidelines.&#x000a0;</p>
      </sec>
      <sec id="article-105841.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>
<italic toggle="yes">Nonopioid analgesic agents</italic>
</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Acetaminophen (paracetamol)</bold>:&#x000a0;This drug is&#x000a0;a safe and effective medication when used correctly. Documented adverse effects depend on the route of administration. If administered&#x000a0;orally or rectally, acetaminophen may cause any of the following:
<list list-type="bullet"><list-item><p>Rash or hypersensitivity reactions (toxic epidermal necrolysis, acute generalized exanthematous pustulosis, and Stevens-Johnson syndrome)</p></list-item><list-item><p>Hematological: anemia, leukopenia, neutropenia, pancytopenia</p></list-item><list-item><p>Nephrotoxicity</p></list-item><list-item><p>Metabolic and electrolyte disorders
<list list-type="bullet"><list-item><p>Decreased serum bicarbonate</p></list-item><list-item><p>Hyponatremia</p></list-item><list-item><p>Hypocalcemia</p></list-item><list-item><p>Hyperammonemia</p></list-item><list-item><p>Hyperchloremia</p></list-item><list-item><p>Hyperuricemia</p></list-item><list-item><p>Hyperglycemia</p></list-item><list-item><p>Hyperbilirubinemia</p></list-item><list-item><p>Elevated alkaline phosphatase&#x000a0;<xref ref-type="bibr" rid="article-105841.r5">[5]</xref><xref ref-type="bibr" rid="article-105841.r6">[6]</xref><xref ref-type="bibr" rid="article-105841.r27">[27]</xref></p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>If administered intravenously, adverse effects include&#x000a0;nausea, vomiting, pruritus, constipation, and abdominal pain.<xref ref-type="bibr" rid="article-105841.r6">[6]</xref>&#x000a0;For pediatric patients, regardless of the route of administration, the most common adverse reactions are&#x000a0;nausea, vomiting, agitation, constipation, pruritus, and atelectasis.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Nonsteroidal anti-inflammatory drugs (NSAIDs)</bold>
<list list-type="bullet"><list-item><p>Gastrointestinal: Nausea, anorexia, dyspepsia, abdominal pain, ulcers, gastrointestinal hemorrhage, perforation, constipation, diarrhea</p></list-item><list-item><p>Cardiovascular: Hypertension, decreased effectiveness of anti-hypertensive medications, myocardial infarction, stroke, and thromboembolic events (last three with selective COX-2 inhibitors); inhibit platelet activation, propensity for bruising, and hemorrhage.</p></list-item><list-item><p>Renal: Salt and water retention, deterioration of kidney function, edema, decreased effectiveness of diuretic medications, decreased urate excretion, hyperkalemia, analgesic nephropathy</p></list-item><list-item><p>Central nervous system: Headache, dizziness, vertigo, confusion, depression, lowering of seizure threshold, hyperventilation (salicylates)</p></list-item><list-item><p>Hypersensitivity: Vasomotor rhinitis, asthma, urticaria, flushing, hypotension, shock.</p></list-item><list-item><p>Hepatotoxicity&#x000a0;<xref ref-type="bibr" rid="article-105841.r8">[8]</xref><xref ref-type="bibr" rid="article-105841.r7">[7]</xref><xref ref-type="bibr" rid="article-105841.r21">[21]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>For a complete list of adverse effects for a particular NSAID, please see the StatPearls article for the&#x000a0;specific drug.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Antidepressant medications</bold>
<list list-type="bullet"><list-item><p><italic toggle="yes">Amitriptyline</italic>: Altered mental status, arrhythmias, constipation, decreased libido, dizziness, drowsiness,&#x000a0;dry mouth,&#x000a0;headache,&#x000a0;hyperhidrosis,&#x000a0;increased risk of suicidal thoughts,&#x000a0;micturition disorders (i.e., urinary retention),&#x000a0;nausea, orthostatic hypotension, tremor, weight gain.</p></list-item><list-item><p><italic toggle="yes">Duloxetine</italic>: Nausea, headache, dry mouth, somnolence, dizziness, abdominal pain, constipation increased blood pressure, increased risk of suicidal thoughts.<xref ref-type="bibr" rid="article-105841.r7">[7]</xref><xref ref-type="bibr" rid="article-105841.r9">[9]</xref><xref ref-type="bibr" rid="article-105841.r28">[28]</xref><xref ref-type="bibr" rid="article-105841.r9">[9]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Antiepileptic medications</bold>
<list list-type="bullet"><list-item><p><italic toggle="yes">Gabapentin</italic>: The most common side effects are dizziness, somnolence, ataxia, peripheral edema, and confusion. Among other,&#x000a0;more serious adverse effects are anaphylaxis, suicidality, depression, fever, infection, steven-Johnson syndrome, angioedema, erythema multiforme, and rhabdomyolysis.<xref ref-type="bibr" rid="article-105841.r29">[29]</xref><xref ref-type="bibr" rid="article-105841.r31">[31]</xref></p></list-item><list-item><p><italic toggle="yes">Pregabalin</italic>: Dizziness, somnolence, headache, peripheral edema, nausea, weight gain, disorientation, blurred vision, increased risk of suicidal thoughts.<xref ref-type="bibr" rid="article-105841.r7">[7]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Local anesthetics</bold>
<list list-type="bullet"><list-item><p><italic toggle="yes">Lidocaine</italic>: Application-site pain, pruritus, erythema, and skin irritation.<xref ref-type="bibr" rid="article-105841.r7">[7]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Opioid agents</bold>
</p>
        <p>Opioids produce a variety&#x000a0;of different systemic adverse effects, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Dysphoria/euphoria</p>
          </list-item>
          <list-item>
            <p>Sedation,</p>
          </list-item>
          <list-item>
            <p>Constipation</p>
          </list-item>
          <list-item>
            <p>Nausea and vomiting</p>
          </list-item>
          <list-item>
            <p>Cough suppression</p>
          </list-item>
          <list-item>
            <p>Miosis</p>
          </list-item>
          <list-item>
            <p>Histamine release (urticaria, pruritus, hypotension, tachycardia)</p>
          </list-item>
          <list-item>
            <p>Endocrine systems suppression</p>
          </list-item>
          <list-item>
            <p>Cardiovascular disorders (i.e., bradycardia)</p>
          </list-item>
          <list-item>
            <p>Respiratory depression</p>
          </list-item>
          <list-item>
            <p>Skeletal muscle rigidity</p>
          </list-item>
          <list-item>
            <p>Tolerance (chronic application)</p>
          </list-item>
          <list-item>
            <p>Physical dependence (chronic application)</p>
          </list-item>
          <list-item>
            <p>Opioid-induced hyperalgesia and/or allodynia (chronic application) <xref ref-type="bibr" rid="article-105841.r17">[17]</xref><xref ref-type="bibr" rid="article-105841.r12">[12]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-105841.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Nonopioid analgesic agents</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Acetaminophen (paracetamol)</bold>: Hypersensitivity to acetaminophen or any of its excipients, severe hepatic impairment, or severe active hepatic disease. Currently, experts are discussing&#x000a0;whether hepatic impairment should be considered a contraindication since it would produce lower levels of the&#x000a0;toxic metabolite, N-acetyl-p-benzoquinone imine (NAPQI).<xref ref-type="bibr" rid="article-105841.r6">[6]</xref><xref ref-type="bibr" rid="article-105841.r32">[32]</xref>&#x000a0;It is worth noting that pregnancy is not a contraindication for acetaminophen administration.</p>
          </list-item>
          <list-item>
            <p><bold>Nonsteroidal anti-inflammatory drugs (NSAIDs)</bold>: Hypersensitivity is the only major contraindication for NSAID use. However, multiple conditions&#x000a0;demand avoidance, temporary suspension, or extremely cautious use, as follows:
<list list-type="bullet"><list-item><p>Age &#x0003e; 50 years and family history of gastrointestinal (GI) disease/bleeding.</p></list-item><list-item><p>Previous GI problems associated with NSAID use (eg., gastritis)</p></list-item><list-item><p>Peptic ulcer</p></list-item><list-item><p>History of personal GI bleeding&#x000a0;</p></list-item><list-item><p>Uncontrolled hypertension</p></list-item><list-item><p>Renal disease</p></list-item><list-item><p>Irritable bowel syndrome</p></list-item><list-item><p>Inflammatory bowel disease</p></list-item><list-item><p>Coronary artery bypass surgery</p></list-item><list-item><p>Gastric bypass surgery</p></list-item><list-item><p>Pregnancy (third trimester)</p></list-item><list-item><p>&#x000a0;Stroke (excluding aspirin)</p></list-item><list-item><p>Transient ischemic attack (excluding aspirin)</p></list-item><list-item><p>Myocardial infarction (excluding aspirin)</p></list-item><list-item><p>Congestive heart failure (excluding aspirin)&#x000a0;<xref ref-type="bibr" rid="article-105841.r7">[7]</xref><xref ref-type="bibr" rid="article-105841.r21">[21]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Antidepressant medications</bold>:
<list list-type="bullet"><list-item><p>Amitriptyline: Hypersensitivity, coadministration&#x000a0;with or within 14 days of&#x000a0;monoamine oxidase inhibitors (MAOIs),&#x000a0;coadministration with cisapride,&#x000a0;recent myocardial infarction, arrhythmias, acute heart failure, severe liver impairment.</p></list-item><list-item><p>Duloxetine: Hypersensitivity,&#x000a0;liver impairment,&#x000a0;severe renal failure&#x000a0;(e.g., CrCl &#x0003c;30 mL/minute) or&#x000a0;end-stage renal disease (ESRD), coadministration&#x000a0;with or within 14 days of MAOIs, concomitant use of linezolid, thioridazine, methylene blue,&#x000a0;or potent CYP1A2 inhibitors,&#x000a0;uncontrolled narrow-angle glaucoma. Precaution in patients with hypertension or cardiac disease.<xref ref-type="bibr" rid="article-105841.r7">[7]</xref><xref ref-type="bibr" rid="article-105841.r9">[9]</xref><xref ref-type="bibr" rid="article-105841.r22">[22]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Antiepileptic medications</bold>: The only established contraindication for gabapentin and pregabalin is hypersensitivity to&#x000a0;the respective drug or&#x000a0;any of its excipients. However, dose adjustment is necessary for patients with compromised renal function.<xref ref-type="bibr" rid="article-105841.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Local anesthetics</bold>: Lidocaine is contraindicated in patients with a previous history of sensitivity to any local anesthetic of the amide-type or any of its excipients. Additionally, the application of lidocaine patches should only be to intact skin.<xref ref-type="bibr" rid="article-105841.r24">[24]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Opioid agents</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Severe respiratory instability</p>
          </list-item>
          <list-item>
            <p>Acute mental&#x000a0;instability or high&#x000a0;suicidal risk</p>
          </list-item>
          <list-item>
            <p>QTc interval over&#x000a0;500 milliseconds (methadone)</p>
          </list-item>
          <list-item>
            <p>Family and/or personal history of substance abuse</p>
          </list-item>
          <list-item>
            <p>Intolerance, serious adverse effects or lack of efficacy to other structurally similar&#x000a0;opioids</p>
          </list-item>
          <list-item>
            <p>Renal or hepatic impairment (depending on the specific drug metabolism and excretion)<xref ref-type="bibr" rid="article-105841.r17">[17]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-105841.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>
<bold> Nonopioid Analgesic Agents</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Acetaminophen (paracetamol)</bold>: It is considered a safe medication if used appropriately. Since toxicity usually&#x000a0;occurs at doses above 150 mg/kg, the therapeutic index is estimated to be around&#x000a0;10.<xref ref-type="bibr" rid="article-105841.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Nonsteroidal anti-inflammatory drugs (NSAIDs)</bold>: There is no need for routine monitoring of NSAID acute administration in healthy patients. However, patients who use NSAIDs chronically (eg., rheumatoid arthritis) and patients considered at increased risk for NSAID toxicity (eg., liver or renal disease) should have an evaluation including CBC, renal, and hepatic function tests as a minimum. Other tests may be ordered depending on clinical suspicion and findings.<xref ref-type="bibr" rid="article-105841.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Antidepressant medications</bold>
<list list-type="bullet"><list-item><p>Amitriptyline: Allow 6 to 8 weeks for an adequate trial. If patients achieve adequate pain relief but do not&#x000a0;tolerate the adverse reactions, consider switching to another TCA such as imipramine or nortriptyline. Consider switching the dose to&#x000a0;bedtime to treat concurrent insomnia or if the patient experiences daytime somnolence.&#x000a0;Patients should be monitored periodically with the following parameters: heart rate, blood pressure, ECG (older adults or preexisting cardiac disease), blood glucose, weight and BMI, electrolyte panel (high-risk population). Additionally, patients should undergo evaluation for suicide ideations and mood lability.</p></list-item><list-item><p>Duloxetine:&#x000a0;Allow 6 to 8 weeks for an adequate trial. Patients should be monitored periodically with blood pressure measurements (especially in patients with hypertension), liver and renal function tests (as clinically indicated), blood glucose and HbA in diabetic patients, and serum sodium in populations at high risk for complications. Additionally, clinicians should evaluate patients for suicide ideations.<xref ref-type="bibr" rid="article-105841.r7">[7]</xref><xref ref-type="bibr" rid="article-105841.r9">[9]</xref><xref ref-type="bibr" rid="article-105841.r28">[28]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Antiepileptic medications</bold>: Healthcare personnel should evaluate&#x000a0;baseline creatinine levels before and during the treatment for patients under treatment for either gabapentin or&#x000a0;pregabalin. Additionally, patients&#x000a0;should do followed up for periodical&#x000a0;screenings of&#x000a0;depression, behavioral changes, and suicidality.<xref ref-type="bibr" rid="article-105841.r31">[31]</xref><xref ref-type="bibr" rid="article-105841.r34">[34]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Local anesthetics</bold>: Since lidocaine has&#x000a0;a narrow therapeutic index, patients with severe hepatic impairment, under prolonged infusions, or with broken or inflamed skin should be monitored for increased plasma levels. Additionally, there are documented cases of methemoglobinemia with a related use of local anesthetics, although they are extremely rare related to patches administration. Signs of methemoglobinemia&#x000a0;include cyanotic skin discoloration and/or abnormal coloration of the blood.<xref ref-type="bibr" rid="article-105841.r24">[24]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Opioid Agents</bold>
</p>
        <p>Clinicians should evaluate their patients on a periodical basis. Follow-ups should focus on the level of pain control and the physical examination (vital signs, signs of misuse, abuse, or addiction; respiratory and mental status; signs or symptoms of hypogonadism or hypoadrenalism).<xref ref-type="bibr" rid="article-105841.r17">[17]</xref></p>
      </sec>
      <sec id="article-105841.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Nonopioid analgesic agents</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Acetaminophen (paracetamol)</bold>: Toxicity develops at 7.5 g/day to 10 g/day or 140 mg/kg, it is&#x000a0;rare at doses of less than 150 mg/kg for an adult or 200 mg/kg for a child. If taken in large amounts, this medication may cause severe liver damage leading to liver transplant or even death.&#x000a0;Although acetaminophen poisoning is observed more frequently&#x000a0;in children, adults usually&#x000a0;present with a more serious and fatal presentation.<xref ref-type="bibr" rid="article-105841.r5">[5]</xref><xref ref-type="bibr" rid="article-105841.r26">[26]</xref><xref ref-type="bibr" rid="article-105841.r35">[35]</xref><xref ref-type="bibr" rid="article-105841.r36">[36]</xref>&#x000a0;In cases of acute overdose, acetaminophen serum levels must be drawn between 4 to 24 hours since&#x000a0;the estimated time of ingestion to determine treatment modality. The tool used to compare toxic levels is known as the&#x000a0;Rumack-Matthew Nomogram.&#x000a0;An acetaminophen level greater than 140 mcg/mL at 4 hours from ingestion requires appropriate treatment with&#x000a0;N-acetyl-cysteine (NAC). Activated charcoal avidly binds&#x000a0;acetaminophen and may be administered in cases that present within the first hour. However, it should not be administered in patients with altered consciousness or patients with increased risk of airway obstruction.<xref ref-type="bibr" rid="article-105841.r26">[26]</xref><xref ref-type="bibr" rid="article-105841.r37">[37]</xref><xref ref-type="bibr" rid="article-105841.r38">[38]</xref><xref ref-type="bibr" rid="article-105841.r39">[39]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Nonsteroidal anti-inflammatory drugs (NSAIDs)</bold>: Most cases&#x000a0;of&#x000a0;acute NSAID overdose are asymptomatic or develop insignificant&#x000a0;self-limiting gastrointestinal symptoms. However, serious complications may occur and include&#x000a0;confusion, headache,&#x000a0;nystagmus,&#x000a0;drowsiness,&#x000a0;blurred vision,&#x000a0;diplopia,&#x000a0;tinnitus,&#x000a0;convulsions, metabolic acidosis, acute renal or liver failure, GI bleeding, and coma.<xref ref-type="bibr" rid="article-105841.r8">[8]</xref><xref ref-type="bibr" rid="article-105841.r40">[40]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Antidepressant medications</bold>:
<list list-type="bullet"><list-item><p>Amitriptyline: Severe signs and symptoms of toxicity include confusion, transient visual hallucinations, mydriasis, agitation, dysrhythmias, severe hypotension, convulsions, hyperreflexia, stupor, drowsiness, muscle rigidity, vomiting, hypothermia, hyperpyrexia, coma, and death. Alteration&#x000a0;in the ECG,&#x000a0;particularly in QRS axis or width, are clinically significant indicators of TCA&#x000a0;toxicity. Other abnormalities include prolonged PR interval, ST-T wave changes, ventricular tachycardia, and fibrillation. The absence of these findings does not exclude TCA poisoning.<xref ref-type="bibr" rid="article-105841.r7">[7]</xref><xref ref-type="bibr" rid="article-105841.r9">[9]</xref><xref ref-type="bibr" rid="article-105841.r28">[28]</xref></p></list-item><list-item><p>Duloxetine:&#x000a0;Signs and symptoms of toxicity&#x000a0;include serotonin syndrome, somnolence,&#x000a0;syncope, tachycardia, seizures, autonomic instability, diarrhea, vomiting, and coma.&#x000a0;There is no antidote available for duloxetine overdose. Nonetheless, cyproheptadine and cooling measures merit consideration&#x000a0;in cases of serotonin syndrome.<xref ref-type="bibr" rid="article-105841.r41">[41]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Antiepileptic medications</bold>:&#x000a0;
<list list-type="bullet"><list-item><p>Gabapentin:&#x000a0;Gabapentin does not carry the risk of overdose or addiction as other pain management medications (eg., opioids). However, gabapentin may&#x000a0;increase a&#x000a0;euphoric state caused by opioids.<xref ref-type="bibr" rid="article-105841.r31">[31]</xref></p></list-item><list-item><p>Pregabalin:&#x000a0;Limited&#x000a0;information is available regarding overdose. The highest documented&#x000a0;accidental overdose occurred&#x000a0;during clinical research and&#x000a0;was 8000 mg. As in the case of gabapentin, pregabalin has no specific antidote.<xref ref-type="bibr" rid="article-105841.r34">[34]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Local anesthetics</bold>: Lidocaine toxicity usually presents&#x000a0;at lidocaine blood concentrations above 5 mcg/mL. Symptoms progress from slurred speech, tinnitus, paresthesias, and dizziness to&#x000a0;loss&#x000a0;of consciousness,&#x000a0;seizures,&#x000a0;cardiac arrhythmias, and cardiorespiratory arrest. Management is supportive (oxygen, IV fluids, and inotropes), and, in cases&#x000a0;of refractory cardiovascular collapse, intravenous lipid emulsion&#x000a0;is indicated.<xref ref-type="bibr" rid="article-105841.r24">[24]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Opioid Agents</bold>
</p>
        <p>Opioid overdose may result in death due to severe respiratory depression. Physicians should suspect opioid toxicity in any patient presenting with altered mental status,&#x000a0;bradypnea, and constricted pupils. Naloxone is indicated for patients with respiratory depression; it may be given&#x000a0;intravenously, intramuscularly, or intranasally. Since naloxone is only active for 30 to 60 minutes, it must be administered through intravenous infusion in cases of&#x000a0;a long-acting opioid overdose.<xref ref-type="bibr" rid="article-105841.r17">[17]</xref><xref ref-type="bibr" rid="article-105841.r42">[42]</xref></p>
      </sec>
      <sec id="article-105841.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Pain management requires a multidisciplinary healthcare team to address accurately and individually pain control for patients. Because adverse effects tend to occur at a much higher rate in patients with specific comorbidities, follow-ups must include a complete history and physical exam to alert for side effects or signs of addiction/misuse.</p>
        <p>Patient education is crucial; providers need to pay close attention to the patient's symptoms and complaints to provide the best healthcare possible and avoid any adverse systemic effects.&#x000a0;Several methods exist to detect any type of drug misuse appropriately. They include the following: state prescription drug monitoring programs,&#x000a0;assessment surveys, adherence check-lists, motivational counseling, urine screening, and dosage forms verification.&#x000a0;Through collaborative interprofessional teamwork, pain management&#x000a0;can confer maximum benefit with minimal downside.</p>
      </sec>
      <sec id="article-105841.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=105841&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=105841">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/105841/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=105841">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-105841.s11">
        <fig id="article-105841.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Regions of the cerebral cortex associated with pain.
Neuroimaging revolutionizes therapeutic approaches to chronic pain Contributed by Wikimedia Commons, Borsook D, Moulton EA, Schmidt KF, Becerra LR (CC BY 2.0)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Schematic_of_cortical_areas_involved_with_pain_processing_and_fMRI" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-105841.s12">
        <fig id="article-105841.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Arachidonic Acid Pathway Contributed from BioMed Central</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="F1.large" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-105841.s13">
        <fig id="article-105841.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Commonly encountered drug interactions with NSAIDs Contributed from the Public Domain, (Wikipedia User: COP2013G02 https://commons.wikimedia.org/w/index.php?curid=9373901)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NSAIDs_DDI" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-105841.s14">
        <fig id="article-105841.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Conversion of arachidonic acid by cyclooxygenase to its metabolites By BQUB14-Msanjose - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=36365139</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Tipus_de_prostaglandines" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-105841.s15">
        <fig id="article-105841.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Opioid Equivalency Tables Contributed by Mamta Bhatnagar MD, MS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Opioid__Equivalency__Tables" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-105841.s16">
        <title>References</title>
        <ref id="article-105841.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <article-title>Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy.</article-title>
            <source>Pain Suppl</source>
            <year>1986</year>
            <volume>3</volume>
            <fpage>S1</fpage>
            <page-range>S1-226</page-range>
            <pub-id pub-id-type="pmid">3461421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aydede</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Does the IASP definition of pain need updating?</article-title>
            <source>Pain Rep</source>
            <year>2019</year>
            <season>Sep-Oct</season>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>e777</fpage>
            <pub-id pub-id-type="pmid">31875184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alcock</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Defining pain: past, present, and future.</article-title>
            <source>Pain</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>158</volume>
            <issue>4</issue>
            <fpage>761</fpage>
            <page-range>761-762</page-range>
            <pub-id pub-id-type="pmid">28301403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Quintner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van Rysewyk</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Reconsidering the International Association for the Study of Pain definition of pain.</article-title>
            <source>Pain Rep</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>e634</fpage>
            <pub-id pub-id-type="pmid">29756084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>J&#x000f3;&#x0017a;wiak-Bebenista</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nowak</surname>
                <given-names>JZ</given-names>
              </name>
            </person-group>
            <article-title>Paracetamol: mechanism of action, applications and safety concern.</article-title>
            <source>Acta Pol Pharm</source>
            <year>2014</year>
            <season>Jan-Feb</season>
            <volume>71</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-23</page-range>
            <pub-id pub-id-type="pmid">24779190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gerriets</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nappe</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <chapter-title>Acetaminophen</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">29493991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finnerup</surname>
                <given-names>NB</given-names>
              </name>
            </person-group>
            <article-title>Nonnarcotic Methods of Pain Management.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Jun</month>
            <day>20</day>
            <volume>380</volume>
            <issue>25</issue>
            <fpage>2440</fpage>
            <page-range>2440-2448</page-range>
            <pub-id pub-id-type="pmid">31216399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ghlichloo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gerriets</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <chapter-title>Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">31613522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Attal</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological treatments of neuropathic pain: The latest recommendations.</article-title>
            <source>Rev Neurol (Paris)</source>
            <year>2019</year>
            <season>Jan-Feb</season>
            <volume>175</volume>
            <issue>1-2</issue>
            <fpage>46</fpage>
            <page-range>46-50</page-range>
            <pub-id pub-id-type="pmid">30318260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finnerup</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Attal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Haroutounian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McNicol</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dworkin</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Gilron</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Haanp&#x000e4;&#x000e4;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hansson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Kamerman</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Raja</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Rice</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Rowbotham</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sena</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Siddall</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.</article-title>
            <source>Lancet Neurol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>162</fpage>
            <page-range>162-73</page-range>
            <pub-id pub-id-type="pmid">25575710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r11">
          <label>11</label>
          <element-citation publication-type="book">
            <chapter-title>Opioids</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>11</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">31643200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Z&#x000f6;llner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Opioids.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2007</year>
            <issue>177</issue>
            <fpage>31</fpage>
            <page-range>31-63</page-range>
            <pub-id pub-id-type="pmid">17087119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Opioids and neuropathic pain.</article-title>
            <source>Pain Physician</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>15</volume>
            <issue>3 Suppl</issue>
            <fpage>ES93</fpage>
            <page-range>ES93-110</page-range>
            <pub-id pub-id-type="pmid">22786465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guy</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bohm</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Losby</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Dowell</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Vital Signs: Changes in Opioid Prescribing in the United States, 2006-2015.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2017</year>
            <month>Jul</month>
            <day>07</day>
            <volume>66</volume>
            <issue>26</issue>
            <fpage>697</fpage>
            <page-range>697-704</page-range>
            <pub-id pub-id-type="pmid">28683056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chakote</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Guggenheimer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Implications of use of opioid-containing analgesics for palliation of acute dental pain.</article-title>
            <source>J Opioid Manag</source>
            <year>2019</year>
            <season>Jan/Feb</season>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-41</page-range>
            <pub-id pub-id-type="pmid">30855721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aubrun</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nouette-Gaulain</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fletcher</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Belbachir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beloeil</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Carles</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cuvillon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dadure</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lebuffe</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marret</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Olivier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sabourdin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zetlaoui</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Revision of expert panel's guidelines on postoperative pain management.</article-title>
            <source>Anaesth Crit Care Pain Med</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>405</fpage>
            <page-range>405-411</page-range>
            <pub-id pub-id-type="pmid">30822542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r17">
          <label>17</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Cohen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ruth</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Preuss</surname>
                <given-names>CV</given-names>
              </name>
            </person-group>
            <chapter-title>Opioid Analgesics</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">29083658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chandrasekharan</surname>
                <given-names>NV</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Roos</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Evanson</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Tomsik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Elton</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2002</year>
            <month>Oct</month>
            <day>15</day>
            <volume>99</volume>
            <issue>21</issue>
            <fpage>13926</fpage>
            <page-range>13926-31</page-range>
            <pub-id pub-id-type="pmid">12242329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Botting</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ayoub</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>COX-3 and the mechanism of action of paracetamol/acetaminophen.</article-title>
            <source>Prostaglandins Leukot Essent Fatty Acids</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>85</fpage>
            <page-range>85-7</page-range>
            <pub-id pub-id-type="pmid">15626590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brooks</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>RO</given-names>
              </name>
            </person-group>
            <article-title>Nonsteroidal antiinflammatory drugs--differences and similarities.</article-title>
            <source>N Engl J Med</source>
            <year>1991</year>
            <month>Jun</month>
            <day>13</day>
            <volume>324</volume>
            <issue>24</issue>
            <fpage>1716</fpage>
            <page-range>1716-25</page-range>
            <pub-id pub-id-type="pmid">2034249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munir</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Enany</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Nonopioid analgesics.</article-title>
            <source>Med Clin North Am</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>91</volume>
            <issue>1</issue>
            <fpage>97</fpage>
            <page-range>97-111</page-range>
            <pub-id pub-id-type="pmid">17164106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scarborough</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Optimal pain management for patients with cancer in the modern era.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2018</year>
            <month>May</month>
            <volume>68</volume>
            <issue>3</issue>
            <fpage>182</fpage>
            <page-range>182-196</page-range>
            <pub-id pub-id-type="pmid">29603142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colloca</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ludman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bouhassira</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dickenson</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Yarnitsky</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Truini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Attal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Finnerup</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Eccleston</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kalso</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Dworkin</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Raja</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>Neuropathic pain.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2017</year>
            <month>Feb</month>
            <day>16</day>
            <volume>3</volume>
            <fpage>17002</fpage>
            <pub-id pub-id-type="pmid">28205574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Beecham</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Nessel</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Lidocaine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>12</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">30969703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trescot</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Datta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Opioid pharmacology.</article-title>
            <source>Pain Physician</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>11</volume>
            <issue>2 Suppl</issue>
            <fpage>S133</fpage>
            <page-range>S133-53</page-range>
            <pub-id pub-id-type="pmid">18443637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r26">
          <label>26</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Agrawal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khazaeni</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <chapter-title>Acetaminophen Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>9</day>
            <pub-id pub-id-type="pmid">28722946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCrae</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>MacIntyre</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Dear</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Long-term adverse effects of paracetamol - a review.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>84</volume>
            <issue>10</issue>
            <fpage>2218</fpage>
            <page-range>2218-2230</page-range>
            <pub-id pub-id-type="pmid">29863746</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wright</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Rizzolo</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>An update on the pharmacologic management and treatment of neuropathic pain.</article-title>
            <source>JAAPA</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>13</fpage>
            <page-range>13-17</page-range>
            <pub-id pub-id-type="pmid">28151738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kukkar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jaggi</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Implications and mechanism of action of gabapentin in neuropathic pain.</article-title>
            <source>Arch Pharm Res</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>237</fpage>
            <page-range>237-51</page-range>
            <pub-id pub-id-type="pmid">23435945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inturrisi</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacology of opioids for pain.</article-title>
            <source>Clin J Pain</source>
            <year>2002</year>
            <season>Jul-Aug</season>
            <volume>18</volume>
            <issue>4 Suppl</issue>
            <fpage>S3</fpage>
            <page-range>S3-13</page-range>
            <pub-id pub-id-type="pmid">12479250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r31">
          <label>31</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Yasaei</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Katta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saadabadi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Gabapentin</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>12</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">29630280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayward</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Irvine</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Can paracetamol (acetaminophen) be administered to patients with liver impairment?</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>81</volume>
            <issue>2</issue>
            <fpage>210</fpage>
            <page-range>210-22</page-range>
            <pub-id pub-id-type="pmid">26460177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bertolini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ottani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guerzoni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tacchi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Leone</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Paracetamol: new vistas of an old drug.</article-title>
            <source>CNS Drug Rev</source>
            <year>2006</year>
            <season>Fall-Winter</season>
            <volume>12</volume>
            <issue>3-4</issue>
            <fpage>250</fpage>
            <page-range>250-75</page-range>
            <pub-id pub-id-type="pmid">17227290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r34">
          <label>34</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Cross</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Viswanath</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <chapter-title>Pregabalin</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>11</month>
            <day>14</day>
            <pub-id pub-id-type="pmid">29261857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Penna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Buchanan</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Paracetamol poisoning in children and hepatotoxicity.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1991</year>
            <month>Aug</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>143</fpage>
            <page-range>143-9</page-range>
            <pub-id pub-id-type="pmid">1931463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Graudins</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Risk prediction of hepatotoxicity in paracetamol poisoning.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>55</volume>
            <issue>8</issue>
            <fpage>879</fpage>
            <page-range>879-892</page-range>
            <pub-id pub-id-type="pmid">28447858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yeates</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of delayed activated charcoal administration in simulated paracetamol (acetaminophen) overdose.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>49</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-4</page-range>
            <pub-id pub-id-type="pmid">10606832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Houston</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Effect of activated charcoal on acetaminophen absorption.</article-title>
            <source>Pediatrics</source>
            <year>1976</year>
            <month>Sep</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>432</fpage>
            <page-range>432-5</page-range>
            <pub-id pub-id-type="pmid">958771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chiew</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Gluud</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brok</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Interventions for paracetamol (acetaminophen) overdose.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Feb</month>
            <day>23</day>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>CD003328</fpage>
            <pub-id pub-id-type="pmid">29473717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hunter</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Dargan</surname>
                <given-names>PI</given-names>
              </name>
            </person-group>
            <article-title>The patterns of toxicity and management of acute nonsteroidal anti-inflammatory drug (NSAID) overdose.</article-title>
            <source>Open Access Emerg Med</source>
            <year>2011</year>
            <volume>3</volume>
            <fpage>39</fpage>
            <page-range>39-48</page-range>
            <pub-id pub-id-type="pmid">27147851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r41">
          <label>41</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Dhaliwal</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Spurling</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Molla</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Duloxetine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">31747213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-105841.r42">
          <label>42</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Oelhaf</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Del Pozo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Azadfard</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Opioid Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">28613731</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
